Valdizán Usón, José Ramón, Idiazábal Alecha, María Angeles · Expert review of neurotherapeutics · 2008 · DOI
This study explores whether a medication called methylphenidate (commonly known as Ritalin) might help people with ME/CFS who experience brain fog, memory problems, and difficulty concentrating. The authors reviewed existing research, including one small study showing positive results, and discussed how this medication works in the brain to boost focus and thinking speed. They suggest methylphenidate could be a promising treatment option worth further investigation for ME/CFS patients.
Cognitive dysfunction is a hallmark symptom of ME/CFS that profoundly impacts patients' quality of life and functioning. This article brings attention to a potential pharmacological treatment for these neuropsychological symptoms and advocates for further clinical investigation of methylphenidate in ME/CFS, which could expand therapeutic options for patients currently lacking effective treatments.
This perspective article does not prove that methylphenidate is effective or safe for ME/CFS patients, as it is not a clinical trial with controlled data. The authors rely heavily on one small study and theoretical extrapolation from ADHD research; robust evidence from large-scale randomized controlled trials in ME/CFS populations is needed before clinical recommendations can be made. The article cannot establish causation or optimal dosing for this patient population.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →